{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T10:02:56Z","timestamp":1790157776499,"version":"4.1.0"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"vor","delay-in-days":139,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007871","name":"European College of Neuropsychopharmacology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuroscience Applied"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.nsa.2026.107014","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T07:13:23Z","timestamp":1779952403000},"page":"107014","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Clinical trials in neurosciences: Need for standards for innovation on clinical outcomes"],"prefix":"10.1016","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8568-4696","authenticated-orcid":false,"given":"Silvia","family":"Zaragoza Domingo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2803-4520","authenticated-orcid":false,"given":"Amy","family":"Pinkham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniella","family":"Tinoco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0750-3818","authenticated-orcid":false,"given":"Jan","family":"Kottner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel","family":"Balabanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8305-2089","authenticated-orcid":false,"given":"Florence","family":"Butlen-Ducuing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Bury-Maynard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nsa.2026.107014_bib1","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/nrd.2016.237","article-title":"Regulatory watch: challenges in drug development for central nervous system disorders: a European medicines agency perspective","volume":"15","author":"Butlen-Ducuing","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.nsa.2026.107014_bib2","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.jval.2012.01.010","article-title":"Reasons for rejection of patient-reported outcome label claims: a compilation based on a review of patient-reported outcome use among new molecular entities and biologic license applications, 2006\u20132010","volume":"15","author":"Demuro","year":"2012","journal-title":"Value Health"},{"key":"10.1016\/j.nsa.2026.107014_bib3","series-title":"Clinical Outcomes in Early-Phase Clinical Trials","year":"2023"},{"key":"10.1016\/j.nsa.2026.107014_bib4","unstructured":"European Medicines Agency (EMA), Patient experience data (PED) reflection paper, (n.d.). https:\/\/www.ema.europa.eu\/en\/patient-experience-data-ped-reflection-paper (accessed November 29, 2025)."},{"key":"10.1016\/j.nsa.2026.107014_bib5","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.3390\/s140203362","article-title":"Gait analysis methods: an overview of wearable and non-wearable systems, highlighting clinical applications","volume":"14","author":"Muro-de-la-Herran","year":"2014","journal-title":"Sensors"},{"key":"10.1016\/j.nsa.2026.107014_bib6","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/j.jval.2023.08.012","article-title":"An updated review of food and drug administration warning and untitled letters for clinical outcome assessment claims between 2013 and 2021","volume":"26","author":"Sams","year":"2023","journal-title":"Value Health"},{"key":"10.1016\/j.nsa.2026.107014_bib7","series-title":"Presentation at the ISCTM-ECNP Joint Autumn Conference 2023, October 5\u20137 2023","article-title":"Are our clinician-rated psychopathology measures fit for purpose decades later?","author":"Schooler","year":"2023"},{"key":"10.1016\/j.nsa.2026.107014_bib8","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/bcp.15907","article-title":"Patient-reported, observer-reported and performance outcomes in qualification procedures at the European Medicines Agency 2013\u20132018","volume":"90","author":"Silva","year":"2024","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.nsa.2026.107014_bib9","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3233\/JPD-202457","article-title":"A patient-centered conceptual model of symptoms and their impact in early parkinson's disease: a qualitative study","volume":"12","author":"Staunton","year":"2022","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.nsa.2026.107014_bib12","unstructured":"U.S. Food and Drug Administration, Roadmap to patient-focused outcome measurement in clinical trials (text version), (n.d.). https:\/\/www.fda.gov\/drugs\/drug-development-tool-ddt-qualification-programs\/roadmap-patient-focused-outcome-measurement-clinical-trials-text-version (accessed November 25, 2025)."},{"key":"10.1016\/j.nsa.2026.107014_bib13","unstructured":"U.S. Food and Drug Administration, Patient-focused drug development: selecting, developing, or modifying fit-for-purpose clinical outcome assessments, (n.d.). https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-focused-drug-development-selecting-developing-or-modifying-fit-purpose-clinical-outcome (accessed November 29, 2025)."},{"key":"10.1016\/j.nsa.2026.107014_bib14","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.euroneuro.2018.06.006","article-title":"New approaches in psychiatric drug development","volume":"28","author":"van der Doef","year":"2018","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.nsa.2026.107014_bib15","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1177\/17407745211073609","article-title":"Constructing and evaluating a validity argument for a performance outcome measure for clinical trials: an example using the Multi-luminance mobility test","volume":"19","author":"Weinfurt","year":"2022","journal-title":"Clin. Trials"},{"key":"10.1016\/j.nsa.2026.107014_bib16","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.euroneuro.2024.02.009","article-title":"Methods for neuroscience drug development: guidance on standardization of the process for defining clinical outcome strategies in clinical trials","volume":"83","author":"Zaragoza Domingo","year":"2024","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.nsa.2026.107014_bib17","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1016\/j.jval.2024.10.235","article-title":"CO159 challenges on outcomes selection along early to late phase clinical trials of drug development: survey to experts in neurosciences drug development","volume":"27","author":"Zaragoza Domingo","year":"2024","journal-title":"Value Health"}],"container-title":["Neuroscience Applied"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S277240852600133X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S277240852600133X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T09:15:29Z","timestamp":1790154929000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S277240852600133X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":15,"alternative-id":["S277240852600133X"],"URL":"https:\/\/doi.org\/10.1016\/j.nsa.2026.107014","relation":{},"ISSN":["2772-4085"],"issn-type":[{"value":"2772-4085","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical trials in neurosciences: Need for standards for innovation on clinical outcomes","name":"articletitle","label":"Article Title"},{"value":"Neuroscience Applied","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nsa.2026.107014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V. on behalf of European College of Neuropsychopharmacology.","name":"copyright","label":"Copyright"}],"article-number":"107014"}}